Croda consensus stays cautious, shares trade below recent high

Croda faces a muted analyst backdrop on the London Stock Exchange, with price targets pointing to limited upside and margins under scrutiny.

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 12:27.

Croda International PLC (GB00BJFFLV09) sits in a transitional phase as the specialty chemicals group trades on the London Stock Exchange with limited upside implied by current analyst price targets. Consensus views now focus on margin resilience and growth in key consumer and life sciences segments, shaping expectations for the stock.

What analysts currently say

The latest data on Croda shows the shares around 3,112 pence, down about 0.2 percent on the day, with a trading range of 3,082 to 3,178 pence. According to MarketScreener, roughly half of covering analysts rate the stock Hold, with a blended target around 3,300 pence, pointing to only a modest potential upside.

A recent note from UBS on European specialty chemicals highlighted how pricing power in personal care ingredients remains under pressure, citing Croda among peers where volume growth is crucial for margin stability. JPMorgan, in a broader sector piece, keeps an overweight stance on higher-growth names such as DSM-Firmenich while being more selective on slower-growing ingredient suppliers like Croda.

Consensus on earnings and margins

For the current financial year, analyst models compiled by MarketScreener show Croda expected to generate around GBP 2.1 billion in revenue and an adjusted operating margin in the low-20s percent, reflecting only a gradual recovery from prior-year levels. Earnings per share consensus for 2026 stands just above 200 pence, illustrating a cautious trajectory rather than a sharp rebound.

Compared with sector peer Symrise, which targets mid-single-digit organic growth longer term, Croda is seen as needing solid volume growth in its consumer care and life sciences franchises to justify its valuation multiples. The valuation spread to peers has narrowed, as investors reassess premium multiples in the broader specialty ingredients space.

The products behind Croda

Croda generates much of its revenue from specialty ingredients used in personal care, including the Sederma active cosmetic ingredients portfolio and surfactants for skin and hair formulations. The company also supplies lipid delivery systems and biotech-derived excipients to pharmaceutical and life sciences customers, broadening its margin profile beyond consumer-only markets.

Where the shares trade today

The Croda International PLC shares (GB00BJFFLV09) trade on 2026-06-23, 10:44, on the London Stock Exchange at around 3,112 pence.

Key data on the Croda International PLC shares

• Company: Croda International Plc
• ISIN: GB00BJFFLV09
• WKN: BJFFLV
• Ticker: CRDA
• Trading venue: London Stock Exchange
• Price (as of 2026-06-23, 10:44): 3,112.00 GBX
• Market cap: approximately 4.2 billion GBP (as of 2026-06-23)
• Sector / industry: Specialty Chemicals / Specialty Ingredients
• Index membership: FTSE 100
• Next earnings date: 2026-07-25

Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation or an offer to buy or sell securities. All data are based on sources deemed reliable but may be subject to change.